Cargando…

DPP4 in Diabetes

Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal dipeptides from a variety of substrates, including cytokines, growth factors, neuropeptides, and the incretin hormones. E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Röhrborn, Diana, Wronkowitz, Nina, Eckel, Juergen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2015
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4515598/ https://www.ncbi.nlm.nih.gov/pubmed/26284071 http://dx.doi.org/10.3389/fimmu.2015.00386

Ejemplares similares

DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
por: Valencia, Inés, et al.
Publicado: (2020)

Editorial: The CXCR4 Ligand/Receptor Family and the DPP4 Protease in High-Risk Cardiovascular Patients
por: Noels, Heidi, et al.
Publicado: (2016)

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
por: Zhang, Jianqiang, et al.
Publicado: (2019)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
por: Lamers, Daniela, et al.
Publicado: (2011)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
por: Baggio, Laurie L., et al.
Publicado: (2020)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

The DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic Retinopathy
por: Dietrich, Nadine, et al.
Publicado: (2016)

DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
por: Nag, Snehasish, et al.
Publicado: (2023)

DPP‐4 inhibition and islet function
por: Ahrén, Bo
Publicado: (2011)

DPP4 inhibition prevents AKI
por: Reichetzeder, Christoph, et al.
Publicado: (2017)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
por: Ahrén, Bo
Publicado: (2008)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
por: Choe, Eun Yeong, et al.
Publicado: (2014)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

COVID-19 and diabetes: Can DPP4 inhibition play a role?
por: Iacobellis, Gianluca
Publicado: (2020)

Antioxidant Effects of DPP-4 Inhibitors in Early Stages of Experimental Diabetic Retinopathy
por: Ramos, Hugo, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

DPP-4 Inhibition and the Path to Clinical Proof
por: Ahrén, Bo
Publicado: (2019)

The regulatory role of DPP4 in atherosclerotic disease
por: Duan, Lihua, et al.
Publicado: (2017)

Immunotherapy With 5, 15-DPP Mediates Macrophage M1 Polarization and Modulates Subsequent Mycobacterium tuberculosis Infectivity in rBCG30 Immunized Mice
por: Ahmad, Faraz, et al.
Publicado: (2021)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors
por: Farr, Amanda M., et al.
Publicado: (2016)

Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects
por: Ahmed, Radwan H., et al.
Publicado: (2016)

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

Influence of nutritional intervention on children with type 1 diabetes mellitus and DPP-4 in serum
por: Dong, Yan-Jun, et al.
Publicado: (2017)

DPP4 Gene Polymorphism Associates With Type 2 Diabetes Mellitus in Older Adults
por: Alves, Elisa, et al.
Publicado: (2020)

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes
por: Kheloussi, Steven, et al.
Publicado: (2021)

A Novel Purification Procedure for Active Recombinant Human DPP4 and the Inability of DPP4 to Bind SARS-CoV-2
por: Xi, Cecy R, et al.
Publicado: (2020)

Isolation of MERS-related coronavirus from lesser bamboo bats that uses DPP4 and infects human-DPP4-transgenic mice
por: Lau, Susanna K. P., et al.
Publicado: (2021)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2sajlki1en35u33hib228faqd8